News

EXCLUSIVE: Genentech/Roche Interview with MS News Today on Promising MS Therapy Ocrelizumab #ECTRIMS 2015

Dr. Peter Chin, a renowned neurologist and Principal Medical Director of Global Neuroscience Development at Genentech, a leading biotechnology company and member of the Roche Group, participated in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros on the companyā€™s promising multiple sclerosis (MS) therapy…

Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015

https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3   Read theĀ articles mentioned in theĀ podcast: #ECTRIMS2015 ā€“ Another Attendee Record #ECTRIMS2015 ā€“ ā€œVitamin D plays important role in MS inflammation.ā€ ā€“ Jorge Correale #ECTRIMS2015 ā€“ ā€œWhen you stop smoking you can decrease the risk of disease progression.ā€ ā€“ Jorge Correale Discovering a New World in…

Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015

Genzyme, aĀ SanofiĀ company, recently announced novel positive 5-year experimental dataĀ from the extension study of LemtradaĀ®Ā (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). The findings were presented today, October 9, at the 31stĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. LemtradaĀ®Ā (alemtuzumab), developedĀ by Genzyme, is…

EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015

A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled ā€œMS developments: transitioning evidence into clinical practiceā€ presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…

Discovering a New World in MS Through Genomics, ECTRIMS 2015

A Satellite Symposia entitled ā€œDiscovering a new world in MSā€ supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 ā€“ 10, 2015. Prof. David Brassat…

Does Sun Exposure in Early Years Delay MS Onset?

Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D levelā€“related factors,” appeared October 7, 2015 in the journal Neurology.

MS Care: A Hot Topic at #ECTRIMS2015

Three ā€œHot Topic Sessionsā€ on multiple sclerosis will take place this afternoon (17:00 ā€“ 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 ā€“ 10. The first session is entitled…

Biomarkers and Predictors For Developing Future Personalized MS Therapies Discussed at ECTRIMS 2015

New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’sĀ 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). TheĀ symposium, being held in Barcelona, Spain, will fosterĀ discussions about development of individualized therapiesĀ forĀ MS patients throughĀ a more targeted and efficient…

Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015

Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…

Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015

The world’sĀ largest generic medicines manufacturer,Ā Teva Pharmaceutical, is at theĀ 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONEĀ®Ā (glatiramer acetate injection), and product candidate for…

ECTRIMS 2015 Congress: a Look at Young Investigator Session II

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily onĀ Teaching Courses in several topics related to multiple sclerosis (MS)…

ECTRIMS 2015 Congress: a Look at Young Investigator Session I

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused onĀ Teaching Courses in several topics related to multiple…

Icometrix Collaborates with Novartis on MSmetrix Software Application, New Data at Upcoming ECTRIMS 2015 Conference

Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AGĀ regardingĀ MSmetrix ā€“ a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…

PCORI Board Approves $83 Million for Research on Multiple Sclerosis, Hepatitis C and Rare Diseases

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approvedĀ an $83 million grant to support 26 patient-centered, comparative effectiveness clinical research (CER) studies on a range of diseases and patient groups. Two of these grants, totaling $29.5 million, will fund research intoĀ the care of patients infected with hepatitis…

Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA

Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…